1. Home
  2. KURA vs HTD Comparison

KURA vs HTD Comparison

Compare KURA & HTD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kura Oncology Inc.

KURA

Kura Oncology Inc.

N/A

Current Price

$13.03

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

HTD

John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

N/A

Current Price

$25.23

Market Cap

906.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
KURA
HTD
Founded
2014
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
906.3M
IPO Year
2015
2003

Fundamental Metrics

Financial Performance
Metric
KURA
HTD
Price
$13.03
$25.23
Analyst Decision
Buy
Analyst Count
11
0
Target Price
$25.56
N/A
AVG Volume (30 Days)
2.2M
47.0K
Earning Date
05-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$67,482,000.00
N/A
Revenue This Year
$28.28
N/A
Revenue Next Year
$106.37
N/A
P/E Ratio
N/A
N/A
Revenue Growth
25.24
N/A
52 Week Low
$7.36
$23.15
52 Week High
$13.90
$26.35

Technical Indicators

Market Signals
Indicator
KURA
HTD
Relative Strength Index (RSI) 64.67 42.54
Support Level $7.96 $24.94
Resistance Level $13.90 $26.18
Average True Range (ATR) 0.68 0.26
MACD 0.09 -0.01
Stochastic Oscillator 73.57 30.01

Price Performance

Historical Comparison
KURA
HTD

About KURA Kura Oncology Inc.

Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, communication services, materials, healthcare, real estate, consumer Staples, and short-term investments.

Share on Social Networks: